Literature DB >> 12496303

Longevity and health care expenditures: the real reasons older people spend more.

Zhou Yang1, Edward C Norton, Sally C Stearns.   

Abstract

OBJECTIVES: In this study, we investigated the relative contributions of both age and time to death to health care expenditures for elderly Medicare beneficiaries. We also analyzed differences in expenditure patterns by age and time to death for various service types and payers.
METHODS: We conducted graphical analysis of person-month level data on 25,994 elderly persons from the 1992-1998 Medicare Current Beneficiary Survey Cost and Use files.
RESULTS: Monthly health care expenditures for elderly people increase substantially with age primarily because mortality rates increase with age and health care expenditures increase with closeness to death. Time to death is the main reason for higher inpatient care expenditures, whereas aging is the main reason for higher long-term care expenditure. DISCUSSION: Both increases in the absolute number of elderly persons and in their longevity will increase future Medicare expenditures. Yet, the expected increase in per person health care expenditures caused by greater longevity of Medicare beneficiaries will be less than expected because of the concentration of expenditures at the end of life rather than during extra years of a relatively healthy life. The latter conclusion may be altered, however, because of other underlying considerations, such as technological change.

Entities:  

Mesh:

Year:  2003        PMID: 12496303     DOI: 10.1093/geronb/58.1.s2

Source DB:  PubMed          Journal:  J Gerontol B Psychol Sci Soc Sci        ISSN: 1079-5014            Impact factor:   4.077


  49 in total

1.  Managing health(-care systems) using information health technologies.

Authors:  Thomas Mathar
Journal:  Health Care Anal       Date:  2011-06

2.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Authors:  Josephine Mauskopf; Anita Brogan; Silas Martin; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Counting backward to health care's future: using time-to-death modeling to identify changes in end-of-life morbidity and the impact of aging on health care expenditures.

Authors:  Greg Payne; Audrey Laporte; Raisa Deber; Peter C Coyte
Journal:  Milbank Q       Date:  2007-06       Impact factor: 4.911

5.  Hospice effect on government expenditures among nursing home residents.

Authors:  Pedro L Gozalo; Susan C Miller; Orna Intrator; Janet P Barber; Vincent Mor
Journal:  Health Serv Res       Date:  2008-02       Impact factor: 3.402

6.  Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model.

Authors:  Helle Wallach Kildemoes; Henrik Støvring; Morten Andersen
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

7.  A deterministic model of home and community care client counts in British Columbia.

Authors:  W L Hare; A Alimadad; H Dodd; R Ferguson; A Rutherford
Journal:  Health Care Manag Sci       Date:  2009-03

8.  Methodological Considerations in Studying Centenarians: Lessons Learned From the Georgia Centenarian Studies.

Authors:  Leonard W Poon; Michal Jazwinski; Robert C Green; John L Woodard; Peter Martin; Willard L Rodgers; Mary Ann Johnson; Dorothy Hausman; Jonathan Arnold; Adam Davey; Mark A Batzer; William R Markesbery; Maria Gearing; Ilene C Siegler; Sandra Reynolds; Jianliang Dai
Journal:  Annu Rev Gerontol Geriatr       Date:  2007-01-01

Review 9.  The effect of population aging on health expenditure growth: a critical review.

Authors:  Claudine de Meijer; Bram Wouterse; Johan Polder; Marc Koopmanschap
Journal:  Eur J Ageing       Date:  2013-05-15

10.  Healthcare costs and obesity prevention: drug costs and other sector-specific consequences.

Authors:  David R Rappange; Werner B F Brouwer; Rudolf T Hoogenveen; Pieter H M Van Baal
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.